Core Viewpoint - The company reported a decline in revenue and profit for the six months ending June 30, 2025, while continuing to expand its clinical research projects both domestically and internationally [1][2] Financial Performance - The company achieved revenue of RMB 3.25 billion, a year-on-year decrease of 3.2% [1] - Profit attributable to shareholders decreased by 22.2% to RMB 383 million during the reporting period [1] - Earnings per share were RMB 0.45 [1] - The board decided not to declare any interim dividend for the six months ending June 30, 2025 [1] Clinical Research Projects - As of June 30, 2025, the company had 409 clinical research projects underway domestically and 237 projects internationally [1] - Among the international projects, 194 were conducting single-region clinical trials primarily in South Korea, Australia, Southeast Asia, Europe, and the United States [1] - The company also had 43 projects conducting multi-region clinical trials across Asia-Pacific, North America, Europe, and Africa, covering various therapeutic areas including oncology, respiratory, cardiovascular, endocrine, rheumatology, infectious diseases, rare diseases, and vaccines [1] Future Strategy - The company aims to embrace regulatory changes, technological innovations, and global expansion to enhance its integrated clinical research service platform [2] - Plans include establishing specialized business teams in specific therapeutic areas to expand client relationships with multinational and large domestic pharmaceutical companies [2] - The company seeks sustainable growth and potential acquisitions to enhance its business and operational capabilities in the U.S. and Europe [2] - Strengthening collaborative relationships within the industry is a priority to consolidate its domestic market position and increase global market share [2] - The goal is to achieve sustainable business development and performance growth, continuously creating returns for shareholders [2]